REVIV3 Procare Company Reports Record Fiscal Year 2023 Financial Results

Published
  • Net sales (revenue) up 907% to $23.52 million for the fiscal year ended May 31, 2023, as compared to the prior year period without the AXIL® business segment
  • Gross profit (as a percentage of sales) increased to 75.3% for the year, as compared to 64.5% for the prior year period
  • Operating expenses as a percentage of net revenues decreased to 66.9% as compared to 73.6% for the prior year period

LOS ANGELES, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Reviv3 Procare Company (“Reviv3,” “we,” “us,” “our,” or the “Company”) (OTCQB: RVIV), an emerging global consumer products company for AXIL® hearing protection and enhancement products and Reviv3® hair and skin care products, today announced financial and operational results for the fiscal year ended May 31, 2023 (“fiscal 2023”).

“As previously disclosed in June 2022, we completed the acquisition of substantially all of the assets of Axil & Associated Brands Corp., a leader in hearing and audio enhancement and protection,” commented Jeff Toghraie, CEO. “The AXIL acquisition fundamentally changed our business model and has led to meaningful growth and laid the foundation for future long-term sustainable growth for the combined Company. As we look to the fiscal year ending 2024 and beyond, we hope to continue to build upon our business model emphasizing innovative products and operational efficiencies to pragmatically grow the business. We have a wonderful shareholder base, world class customers and committed employees – we are excited for what is to come,” stated Mr. Toghraie.

“We had a strong finish to our fiscal year and achieved the milestone of four consecutive quarters of profitability with record year-end revenues and net income,” remarked Monica Diaz Brickell, CFO. “AXIL has been beyond additive to our business and after the successful integration of AXIL and its staff, our revenue grew by an impressive 907% from the prior year. These results underscore the strength of the acquisition - a credit to the AXIL staff, our legacy staff and our management team. During fiscal 2023, we managed to increase our gross profit as a percentage of sales to over 75% from around 64% for the prior year, while reducing our operating expense to less than 67% compared to prior year’s 73% - a meaningful financial achievement. As we look to 2024, we have a goal of accelerating revenue growth and market share expansion,” concluded Ms. Brickell.

Business and Product Success Stories for fiscal 2023

Our primary business model focused on AXIL® during fiscal 2023. We continue to operate the Reviv3 brand in addition to AXIL®, but our focus in the fiscal year ending May 31, 2024 will be on AXIL®.

  • On June 22, 2022, we announced the acquisition of AXIL®, as noted above.
  • On January 25, 2023, we announced our expanded relationship with “Bass Pro Shops®” with the introduction of “AXIL GS Extreme 2.0 Nationwide®.”
  • On January 31, 2023, we announced a new distribution agreement with JAMMAS SP. O.O. for distribution of AXIL® portfolio of products in Poland.
  • On February 16, 2023, we announced expanded distribution of AXIL® products through distribution agreement with “GMK Ltd.,” for United Kingdom.
  • On February 22, 2023, we announced accelerated European rollout of our AXIL® product line through a new distribution agreement in Switzerland with “Tagforce AG”, which provided us with a streamlined supply chain in Europe.
  • On February 28, 2023, we announced an exclusive agreement with “Berretta Holding” for distribution of AXIL® products in Australia.
  • On April 17, 2023, we announced a new distribution agreement for AXIL® products with “DEFSEC SYSTEMS” for Malaysia.
  • On May 1, 2023, we announced a new distribution agreement of AXIL® products with “FARM SRL” for Italy.
  • On May 10, 2023, we announced the release of the next generation “XCOR True Wireless EarPro Buds®” hearing enhancement and protection by AXIL®.
  • On May 15, 2023, we announced a multi-year licensing agreement with NASCAR®.

Financial Tables

REVIV3 PROCARE COMPANY AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
         
  May 31, 2023   May 31, 2022  
ASSETS        
CURRENT ASSETS:        
Cash $4,832,682  $373,731 
Accounts receivable, net  417,016   105,921 
Inventory, net  1,311,864   323,388 
Prepaid expenses and other current assets  801,360    
         
Total Current Assets  7,362,922   803,040 
         
OTHER ASSETS:        
Property and equipment, net  157,463   29,145 
Intangible assets, net  382,674    
Right of use asset  101,845   45,453 
Other assets  12,195   16,277 
Goodwill  2,152,215    
         
Total Other Assets  2,806,392   90,875 
         
TOTAL ASSETS $10,169,314  $893,915 
         
LIABILITIES AND STOCKHOLDERS’ EQUITY        
         
CURRENT LIABILITIES:        
Accounts payable $908,606  $458,263 
Customer deposits  183,688   16,522 
Equipment payable, current  2,200   3,300 
Contract liabilities, current  827,106    
Notes payable  172,588   156,300 
Due to related party  158,072   25,452 
Lease Liability, current  65,824   47,166 
Income Tax Liability  230,913    
Other current liabilities  305,664    
         
Total Current Liabilities  2,854,661   707,003 
         
LONG TERM LIABILITIES:        
Equipment payable     2,200 
Lease liability, long term  36,752    
Contract liabilities, long term  605,942    
         
Total Long Term Liabilities  642,694   2,200 
         
Total Liabilities  3,497,355   709,203 
         
         
STOCKHOLDERS’ EQUITY:        
Preferred stock, $0.0001 par value; 300,000,000 shares authorized; 250,000,000 and no shares issued and outstanding as of May 31, 2023 and May 31, 2022, respectively  25,000    
Common stock, $0.0001 par value: 450,000,000 shares authorized; 117,076,949 and 41,945,881 shares issued, and outstanding as of May 31, 2023 and May 31, 2022, respectively  11,708   4,195 
Additional paid-in capital  10,102,243   5,472,084 
Accumulated deficit  (3,466,992)  (5,291,567)
         
Total Stockholders’ Equity  6,671,959   184,712 
         
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $10,169,314  $893,915 

REVIV3 PROCARE COMPANY AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS
         
  For the Fiscal Years Ended 
  May 31,  May 31, 
   2023   2022 
         
Sales, net $23,521,027  $2,336,257 
         
Cost of sales  5,810,216   828,586 
         
Gross profit  17,710,811   1,507,671 
         
OPERATING EXPENSES:        
Marketing and selling expenses  11,675,206   1,199,305 
Compensation and related taxes  1,347,839   15,129 
Professional and consulting expenses  1,420,990   232,774 
General and administrative  1,282,565   271,866 
         
Total Operating Expenses  15,726,600   1,719,074 
         
INCOME (LOSS) FROM OPERATIONS  1,984,211   (211,403)
         
OTHER INCOME (EXPENSE):        
Gain on debt settlement  50,500   35,000 
Other income  16,829    
Interest income  6,469   36 
Interest expense and other finance charges  (2,521)  (6,536)
         
Other Income (Expense), Net  71,277   28,500 
         
INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES  2,055,488   (182,903)
         
Provision for income taxes  230,913    
         
NET INCOME (LOSS) $1,824,575  $(182,903)
         
NET INCOME (LOSS) PER COMMON SHARE:        
Basic $0.02  $(0.00)
Diluted $0.01  $(0.00)
         
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:        
Basic  112,895,411   41,945,881 
Diluted  357,385,274   41,945,881 

REVIV3 PROCARE COMPANY AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS
         
  For the Fiscal Years Ended 
  May 31, 2023  May 31, 2022 
         
CASH FLOWS FROM OPERATING ACTIVITIES        
Net income (loss) $1,824,575  $(182,903)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:        
Depreciation and amortization  95,179   7,871 
Bad debts  76,969   6,941 
Inventory obsolescence     71,481 
Stock based compensation  207,342   21,967 
Gain on debt forgiveness  (50,500)  (35,000)
Non cash lease expense     (1,713)
Change in operating assets and liabilities:        
Accounts receivable  (160,277)  (21,985)
Inventory  353,985   95,983 
Prepaid expenses and other current assets  (661,115)  2,430 
Deposits  (3,810)   
Accounts payable and accrued expenses  215,175   (701)
Other current liabilities  630,897    
Customer deposits     (90,426)
Contract liabilities  389,716    
         
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES  2,918,136   (126,055)
         
CASH FLOWS FROM INVESTING ACTIVITIES        
Cash acquired on business acquisition  1,066,414    
Purchase of property and equipment  (65,650)   
         
NET CASH PROVIDED BY INVESTING ACTIVITIES  1,000,764    
         
CASH FLOWS FROM FINANCING ACTIVITIES        
Cash raised for common stock to be issued  447,850    
Proceeds from loan payable     35,000 
Repayment of equipment financing  (3,300)  (3,300)
Repayment of note payable  (37,119)   
Advances (payments) from a related party  132,620   (28,851)
         
NET CASH PROVIDED BY FINANCING ACTIVITIES  540,051   2,849 
         
NET INCREASE (DECREASE) IN CASH  4,458,951   (123,206)
         
CASH - Beginning of year  373,731   496,937 
         
CASH - End of year $4,832,682  $373,731 
         
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:        
Cash paid during the period for:        
Interest $2,521  $500 
Income taxes $  $ 
         
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:        
Stock issued for business combination $4,007,480  $ 
Right of use assets recognized as lease liability $131,970  $ 
Tangible assets (excluding cash) acquired in business combination $1,740,729  $ 
Intangible assets acquired in business combination $456,945  $ 
Goodwill acquired in business combination $2,152,215  $ 
Liabilities assumed in business combination $1,408,823  $ 
 

About Reviv3

Reviv3 Procare Company (OTCQB: RVIV) is an emerging global e-commerce consumer products company. The Company is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, under the AXIL® brand and premium hair and skincare products under its in-house Reviv3 Procare brand - selling products in the United States, Canada, the European Union and throughout Asia. To learn more, please visit the Company's website at www.reviv3.com and, for the AXIL® brand, visit www.goaxil.com.

Forward-Looking Statements

This press release contains a number of forward-looking statements within the meaning of the federal securities laws. The use of words such as “future,” “hope” and “goal,” among others, generally identify forward-looking statements. These forward-looking statements are based on currently available information, and management’s beliefs, projections, and current expectations, and are subject to a number of significant risks and uncertainties, many of which are beyond management’s control and may cause Reviv3’s results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include, among other things: (i) Reviv3’s ability to grow net sales as anticipated and perform in accordance with guidance; (ii) our ability to generate sufficient revenue to support Reviv3’s operations and to raise additional funds or obtain other forms of financing as needed on acceptable terms, or at all; (iii) potential difficulties or delays Reviv3 may experience in implementing its cost savings and efficiency initiatives, including integrating the AXIL® brand; (iv) Reviv3’s ability to compete effectively with other hair and skincare companies and hearing enhancement and protection companies; (v) the concentration of Reviv3’s customers, potentially increasing the negative impact to Reviv3 by changing purchasing or selling patterns; (vi) changes in laws or regulations in the United States and/or in other major markets, such as China, in which Reviv3 operates, including, without limitation, with respect to taxes, tariffs, trade policies or product safety, which may increase Reviv3’s product costs and other costs of doing business, and reduce Reviv3’s earnings; and (vi) the impact of unstable market and general economic conditions on Reviv3’s business, financial condition and stock price, including inflationary cost pressures, decreased discretionary consumer spending, supply chain disruptions and constraints, labor shortages, ongoing economic disruption, including the effects of the Ukraine-Russia conflict and ongoing impact of COVID-19, and other downturns in the business cycle or the economy. There can be no assurance as to any of these matters, and potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. Other important factors that may cause actual results to differ materially from those expressed in the forward-looking statements are discussed in the Company’s filings with the U.S. Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Except as required by law, Reviv3 does not assume any obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

Investor Relations:Reviv3 Investor Relations Team(888) 638-8883investors@reviv3.com

Source: Reviv3 Procare Company

In This Story